|
|
||||||||
FORUM |
From Clinical Research and Development, Pfizer Global Research and Development, New London, Connecticut (Dr Harty and Dr Power) and Clinical Research and Development, Pfizer Global Research and Development, Ann Arbor, Michigan (Dr Johnson).
Race and ethnicity are terms that are commonly used to categorize subjects in medical research. Advances in genetics and the emerging discipline of pharmacogenomics have brought these terms under scrutiny, with arguments either for the continued use or for the abandonment of these terms generating strong views. As pharmacogenomics research develops, we may find that more accurate and specific descriptions of relevant variation in genes will reduce the value that these imprecise descriptors have in predicting how people will respond to drug therapies.
Key Words: Pharmacogenomics race ethnicity genetics
Address for reprints: Aidan Power, MB, BCh, MRCPsych, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320; e-mail: aidan.c.power{at}pfizer.com.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
V. L. Bonham, T. Citrin, S. M. Modell, T. H. Franklin, E. W. B. Bleicher, and L. M. Fleck Community-Based Dialogue: Engaging Communities of Color in the United States' Genetics Policy Conversation Journal of Health Politics Policy and Law, June 1, 2009; 34(3): 325 - 359. [Abstract] [PDF] |
||||
![]() |
R. Temple and N. L. Stockbridge BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective Ann Intern Med, January 2, 2007; 146(1): 57 - 62. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |